GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » YoY EPS Growth

Relmada Therapeutics (STU:4E2) YoY EPS Growth : 29.29% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Relmada Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2024 was 29.29%.

Relmada Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was €-0.55.


Relmada Therapeutics YoY EPS Growth Historical Data

The historical data trend for Relmada Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics YoY EPS Growth Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 -29.15 -102.33 21.05 39.88

Relmada Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.39 48.30 36.00 18.57 29.29

Relmada Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Relmada Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-3.008--5.003)/ | -5.003 |
=39.88 %

Relmada Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EPS Growth (Q: Jun. 2024 )
=(Earnings per Share (Diluted) (Q: Jun. 2024 )-Earnings per Share (Diluted) (Q: Jun. 2023 )) / | Earnings per Share (Diluted) (Q: Jun. 2023 )) |
=(-0.548--0.775)/ | -0.775 |
=29.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relmada Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Relmada Therapeutics Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines